Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Average Target Price from Brokerages

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) has been given an average rating of "Buy" by the seven analysts that are covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $23.00.

AURA has been the topic of several analyst reports. BTIG Research upped their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a "buy" rating in a research note on Friday, October 18th. Scotiabank upped their price objective on Aura Biosciences from $20.00 to $23.00 and gave the company a "sector outperform" rating in a research report on Friday, October 18th. Cowen reissued a "buy" rating on shares of Aura Biosciences in a report on Friday, October 18th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $22.00 price target on shares of Aura Biosciences in a report on Thursday, November 14th.

Aura Biosciences Trading Down 2.6 %

NASDAQ:AURA traded down $0.21 during trading hours on Friday, reaching $7.89. 119,197 shares of the company traded hands, compared to its average volume of 106,918. The business's 50-day moving average price is $8.38 and its two-hundred day moving average price is $8.93. Aura Biosciences has a 1 year low of $6.63 and a 1 year high of $12.38. The stock has a market capitalization of $394.11 million, a P/E ratio of -4.56 and a beta of 0.30.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.02. As a group, equities analysts anticipate that Aura Biosciences will post -1.67 EPS for the current year.

Insider Transactions at Aura Biosciences

In related news, insider Janet Jill Hopkins sold 11,822 shares of the business's stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.36, for a total transaction of $110,653.92. Following the completion of the sale, the insider now directly owns 151,693 shares in the company, valued at approximately $1,419,846.48. The trade was a 7.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Los Pinos Elisabet De sold 15,955 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the transaction, the insider now owns 304,692 shares in the company, valued at $2,336,987.64. The trade was a 4.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 38,531 shares of company stock worth $345,454 in the last ninety days. Insiders own 5.40% of the company's stock.

Institutional Investors Weigh In On Aura Biosciences

Hedge funds have recently modified their holdings of the business. Franklin Resources Inc. lifted its holdings in Aura Biosciences by 14.8% during the third quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company's stock valued at $15,571,000 after purchasing an additional 215,597 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Aura Biosciences by 4.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company's stock valued at $8,990,000 after purchasing an additional 39,379 shares during the period. State Street Corp lifted its stake in shares of Aura Biosciences by 3.7% during the 3rd quarter. State Street Corp now owns 754,803 shares of the company's stock valued at $6,725,000 after buying an additional 26,841 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Aura Biosciences by 20.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company's stock worth $1,892,000 after buying an additional 41,711 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in Aura Biosciences by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company's stock worth $1,233,000 after buying an additional 3,612 shares in the last quarter. Institutional investors own 96.75% of the company's stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.